Syndevrx, Inc. reported raising $16.3M in an amended private placement filing on March 20, 2017
Mar 22, 2017 - RelSci Data Update
Investments

Background Information:
Syndevrx, Inc. develops treatments for metabolic-related diseases. Its product includes SDX-7320, a polymer conjugate of fumagillol that releases a pharmacologically active small molecule fumagillol derivative in vivo. The company was founded by James M. Shanahan and Bradley J. Carver and is headquartered in Cambridge, MA.
In The News:
Syndevrx, Inc. reported raising $1.5M in an amended private placement filing on November 9, 2017
November 11, 2017  •  RelSci
Uveitis Pipeline and Clinical Trials Review Research Reports for 2015
October 29, 2015  •  PR Newswire
Uveitis Therapeutic Development and Pipeline Review H1 2015
April 15, 2015  •  PR Newswire
Syndevrx, Inc. develops treatments for metabolic-related diseases. Its product includes SDX-7320, a polymer conjugate of fumagillol that releases a pharmacologically active small molecule fumagillol derivative in vivo. The company was founded by James M. Shanahan and Bradley J. Carver and is headquartered in Cambridge, MA.